Affordable Chinese Immunotherapy Transforms Cancer Treatment in India
Chinese medicines bring relief to India’s cancer patients
The Economic TimesImage: The Economic Times
In India, the rising use of affordable Chinese immunotherapy drugs is transforming cancer treatment, making it accessible for patients previously priced out due to high costs of Western medicines. Collaborations between Indian and Chinese pharmaceutical companies are increasing the availability of these therapies, which have shown promising results in clinical responses.
- 01Chinese immunotherapy drugs are significantly cheaper than Western alternatives, improving access for Indian patients.
- 02Doctors report positive clinical responses from Chinese-developed therapies used in conjunction with chemotherapy.
- 03The shift towards affordable treatment options addresses the financial burden faced by cancer patients in India.
- 04Indian pharmaceutical companies are actively partnering with Chinese firms to bring innovative cancer treatments to market.
- 05Low-dose immunotherapy strategies are being explored to further reduce costs and expand access.
Advertisement
In-Article Ad
The landscape of cancer treatment in India is undergoing a transformation with the introduction of affordable Chinese immunotherapy drugs. Vijay Patil, a cancer specialist at PD Hinduja Hospital in Mumbai, has successfully treated patients with lower-cost alternatives that have shown strong clinical responses. These therapies, developed in China and marketed through partnerships with Indian companies, are filling a critical gap left by the high prices of Western immunotherapy drugs, which can cost between ₹1 lakh ($1,200 USD) to ₹5 lakh ($6,000 USD) per session.
A study published in The Lancet indicates that 34-84% of cancer patients in India face catastrophic expenditure on treatment, making affordable options vital. Doctors like Sunil Chopade from Jaslok Hospital advocate for the adoption of effective Chinese immunotherapy molecules, which are now approved for various cancers in India. The cost of these treatments is around ₹50,000 ($600 USD) per session, significantly lower than Western counterparts, allowing for better patient adherence to long-term care.
Indian pharmaceutical companies are capitalizing on this trend. For instance, Intas Pharma and Glenmark have launched drugs licensed from Chinese firms, offering hope for patients who previously struggled with financial toxicity. Experts predict that within a decade, Chinese medicines will increasingly replace those from the US and Europe in the Indian market, driven by their affordability and efficacy.
Advertisement
In-Article Ad
The availability of affordable Chinese immunotherapy drugs is expected to significantly reduce the financial burden on cancer patients in India, allowing more individuals to access necessary treatments.
Advertisement
In-Article Ad
Reader Poll
Do you believe affordable cancer treatments should be prioritized in India?
Connecting to poll...
Read the original article
Visit the source for the complete story.



